PF06650833 is primarily used in pharmaceutical research and development, particularly as an investigational compound in the treatment of inflammatory and autoimmune diseases. It functions as a potent and selective inhibitor of IRAK4 (Interleukin-1 Receptor-Associated Kinase 4), a key enzyme in the signaling pathways of the innate immune system. By targeting IRAK4, it helps modulate immune responses, making it a potential therapeutic agent for conditions like rheumatoid arthritis, psoriasis, and other inflammatory disorders. Its application is currently focused on clinical trials to evaluate its efficacy, safety, and potential as a novel treatment option.